119th (2025–2027)
H.Res. 803
This resolution urges the Food and Drug Administration to conduct a new safety review of medication abortion drugs, citing concerns about their expansion and what sponsors claim are underreported complication rates. The resolution references several policy changes that have made these medications more accessible, including the removal of in-person dispensing requirements and the FDA's September 2025 approval of a generic version of mifepristone. Sponsors argue that independent research suggests complications occur at rates significantly higher than currently reported by the FDA and drug manufacturers. The resolution does not authorize any funding or establish a timeline; it simply calls on the FDA director to reevaluate the safety data and release a public review that includes real-world outcomes and complications. This is a nonbinding resolution expressing the House's position rather than legislation that changes law or policy directly.